ALKS Stock Recent News

ALKS LATEST HEADLINES

ALKS Stock News Image - seekingalpha.com

Alkermes plc is a mid-cap and quite profitable commercial-stage biopharma company, and we are revisiting it today for the first time in a year. The company just reported Q2 financial results, with progress around revenue growth from its product portfolio and some pipeline progress. Analyst commentary is positive, and Alkermes has a rock-solid balance sheet with over $1 billion in net cash and no long-term debt.

seekingalpha.com 2025 Jul 30
ALKS Stock News Image - zacks.com

ALKS beats second-quarter estimates as proprietary product sales rise 14% y/y, offsetting weaker manufacturing and royalty revenues.

zacks.com 2025 Jul 30
ALKS Stock News Image - seekingalpha.com

Alkermes plc (NASDAQ:ALKS ) Q2 2025 Earnings Call July 29, 2025 8:00 AM ET Company Participants Blair C. Jackson - Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO C.

seekingalpha.com 2025 Jul 29
ALKS Stock News Image - zacks.com

The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com 2025 Jul 29
ALKS Stock News Image - zacks.com

Alkermes (ALKS) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.72 per share a year ago.

zacks.com 2025 Jul 29
ALKS Stock News Image - prnewswire.com

—    Second Quarter Revenues of $390.7 Million — —    GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 — —    Company Reiterates 2025 Financial Expectations — —    Alkermes to Present Detailed Vibrance-1 Results at Upcoming World Sleep Congress — DUBLIN , July 29, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2025. "Our second quarter results reflect strong performance across all three of our proprietary products and robust profitability and cash flow generation," said Richard Pops, Chief Executive Officer of Alkermes.

prnewswire.com 2025 Jul 29
ALKS Stock News Image - zacks.com

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com 2025 Jul 22
ALKS Stock News Image - zacks.com

Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.

zacks.com 2025 Jul 22
ALKS Stock News Image - investors.com

Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.

investors.com 2025 Jul 21
ALKS Stock News Image - prnewswire.com

– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – – Alixorexton Demonstrated Robust and Consistent Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition at All Doses Tested – – Alixorexton Was Generally Well Tolerated at All Doses Tested – – Detailed Results to Be Presented at Upcoming World Sleep Congress – – Data Support Advancement of Alixorexton to Phase 3 Development in Narcolepsy – DUBLIN , July 21, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1). Alixorexton, formerly referred to as ALKS 2680, is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in phase 2 development as a onc

prnewswire.com 2025 Jul 21
10 of 50